![AstraZeneca said its Evusheld treatment retains neutralising activity against the 'emerging and highly transmissible' Omicron BA.2 sub-variant. AP](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/UF2PRLAPMYQMPSUTWBLQBX2OEY.jpg?smart=true&auth=0ee2ac1cd85f1ff75421b496e656d4bdbcff32b720a4923206aa9d44d15e9fb8&width=400&height=225)
AstraZeneca said its Evusheld treatment retains neutralising activity against the 'emerging and highly transmissible' Omicron BA.2 sub-variant. AP
AstraZeneca said its Evusheld treatment retains neutralising activity against the 'emerging and highly transmissible' Omicron BA.2 sub-variant. AP
AstraZeneca coronavirus drug offers protection against Omicron sub-variants in study
AstraZeneca said its Evusheld treatment retains neutralising activity against mutation